Skip to main content
Advanced Technical IVT

thrombotic microangiopathy

Also written as: TMA — Thrombotic Microangiopathy

Group of disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ dysfunction including acute kidney injury.

Full Definition

Thrombotic microangiopathy (TMA) encompasses several conditions including hemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), and atypical HUS, all characterized by endothelial damage leading to microvascular thrombosis. In pediatric patients, TMA most commonly presents as post-diarrheal HUS following Shiga toxin-producing E. coli infection. The classic triad includes microangiopathic hemolytic anemia (with schistocytes on blood smear), thrombocytopenia, and acute kidney injury. Atypical forms may be complement-mediated or associated with medications, malignancy, or genetic mutations. Treatment varies by etiology and may include supportive care, plasma exchange, complement inhibitors, or specific targeted therapies.

Usage

Usage note: Commonly abbreviated as TMA; encompasses multiple related but distinct conditions.

In Context

  • "The child presented with classic signs of thrombotic microangiopathy following a diarrheal illness." — Emergency department consultation note
  • "Genetic testing for atypical thrombotic microangiopathy revealed a complement factor H mutation." — Pediatric hematology-oncology report

Also known as

TMA microangiopathic syndrome

Don't confuse with

disseminated intravascular coagulation idiopathic thrombocytopenic purpura

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON